InsidersTradesSigma
Follow the Athenex, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Athenex, Inc. has recorded 152 reports. The latest transaction was disclosed on 8 May 2023 (Attribution). Among the most active insiders: LAU JOHNSON YIU NAM. All data is openly available.
152
Insider Decl.
n/a
Thresholds
€272,800
15 ops.
Buy Volume
n/a
n/a
Sell Volume
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 May 2023
Declarations152 total
3,603 shares@ US$1.361.3% of flowCommon StockSEC:0001209191-23-027948:0
8,382 shares@ US$1.361.9% of flowCommon StockSEC:0001209191-23-027951:0
368 shares@ US$1.363.2% of flowCommon StockSEC:0001209191-23-027942:0
383 shares@ US$1.3053.2% of flowCommon StockSEC:0001209191-23-025394:0
6,513 shares@ US$1.30518.3% of flowCommon StockSEC:0001209191-23-025413:0
5,747 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025401:0
3,642 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025397:0
8,813 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025410:0
2,300 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025408:0
8,736 shares@ US$1.3051.9% of flowCommon StockSEC:0001209191-23-025405:0
3,755 shares@ US$1.3051.3% of flowCommon StockSEC:0001209191-23-025403:0
4,017 shares@ US$1.221.3% of flowCommon StockSEC:0001209191-23-024010:0
9,344 shares@ US$1.221.9% of flowCommon StockSEC:0001209191-23-024005:0
410 shares@ US$1.223.2% of flowCommon StockSEC:0001209191-23-024016:0
360 shares@ US$1.393.2% of flowCommon StockSEC:0001209191-23-021233:0
3,525 shares@ US$1.391.3% of flowCommon StockSEC:0001209191-23-021230:0
8,201 shares@ US$1.391.9% of flowCommon StockSEC:0001209191-23-021224:0
5,519 shares@ US$1.941.8% of flowCommon StockSEC:0001209191-23-018191:0
2,526 shares@ US$1.941.4% of flowCommon StockSEC:0001209191-23-018198:0
258 shares@ US$1.943.3% of flowCommon StockSEC:0001209191-23-018206:0
1,788 shares@ US$2.741.4% of flowCommon StockSEC:0001209191-23-013263:0
625 sharesCommon StockSEC:0001209191-23-013223:0
182 shares@ US$2.743.3% of flowCommon StockSEC:0001209191-23-013246:0
1,591 shares@ US$2.740.7% of flowCommon StockSEC:0001209191-23-013259:0
25 of 152 declarations
关于 Athenex, Inc.
Athenex, Inc.（股票代码：ATNX）是一家在美国上市的生物制药公司，其普通股在纳斯达克全球精选市场交易，对于关注 SEC 披露和内幕交易的投资者而言，它是一个纽约证券交易所/纳斯达克风格的美国公开市场名称。该公司历史上总部位于美国纽约州布法罗。它于 2003 年 11 月成立为 Kinex Pharmaceuticals LLC，于 2004 年 2 月开始运营，并于 2012 年 12 月转变为特拉华州公司，之后更名为 Athenex。([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai)) 从商业模式的角度来看，Athenex 是一家专注于肿瘤学的生物技术公司，集研发、生产和专业商业化于一体。其核心科学叙事围绕通过 Orascovery 平台进行的口服紫杉烷递送，包括口服紫杉醇和恩西奎达，以及 Src 激酶抑制、TCR-T 细胞疗法和精氨酸剥夺方法等其他技术平台。该公司的历史管线还包括 KX-01 和 KX-02 等候选药物。除了临床阶段开发，Athenex 还通过 Athenex Pharmaceutical Division (APD) 运营商业渠道，并通过 Athenex Pharma Solutions (APS) 开展 503B 复合相关活动。([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) 从地理上看，Athenex 对于一家中型生物技术公司而言，其业务范围相对较广，在美国布法罗、克拉伦斯、克兰福德、休斯顿和芝加哥设有办事处和设施，此外还在香港、台北、重庆多个地点、曼彻斯特、危地马拉城和布宜诺斯艾利斯设有运营或办事处。这种国际化设置支持了临床开发、生产和商业执行，但也凸显了组织的复杂性。在竞争方面，Athenex 在一个拥挤的全球肿瘤市场中运营，资本获取、监管里程碑和试验结果是关键的差异化因素。其定位更多地取决于其技术能否产生具有临床意义和可批准的产品，而不是规模。([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) 近期 SEC 披露和文件显示，该公司已进入一个困难的战略和财务阶段，管理层专注于在高度不确定性下保留和推进剩余平台资产。对于投资者，特别是筛选 Form 4 内幕交易的法国、比利时和瑞士读者，Athenex 应被视为一个高风险的生物技术案例研究，而不是一个成熟的商业制药平台。投资论点历史上取决于管线执行、监管进展以及将科学前景转化为持久商业价值的能力。([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai))
